Education
About Us
Working with TipRanks
Follow Us
Hookipa Pharma (HOOK)
:HOOK
HOOK Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.72 - $6.69
Previous CloseN/A
Volume38.61K
Average Volume (3M)58.28K
Market Cap
$14.52M
Enterprise Value-$25.04M
Total Cash (Recent Filing)$40.28M
Total Debt (Recent Filing)$596.00K
Price to Earnings (P/E)―
Beta2.25
Next Earnings
Aug 07, 2025EPS Estimate
-0.61Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.23
Shares Outstanding9,799,053
10 Day Avg. Volume48,703
30 Day Avg. Volume58,285
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.42
Price to Sales (P/S)0.00
P/FCF Ratio-0.28
Enterprise Value/Market Cap-1.73
Enterprise Value/Revenue-0.16
Enterprise Value/Gross Profit-2.89
Enterprise Value/Ebitda0.13
Forecast
1Y Price Target
$2.00Price Target Upside66.67% Upside
Rating ConsensusHold
Number of Analyst Covering1
Hookipa Pharma News
PremiumCompany Announcements
Hookipa Pharma Sells Assets to Gilead Sciences
PremiumCompany Announcements
Hookipa Pharma Seeks Validation for Stockholder Meetings
Bulls Say, Bears Say
Bulls Say
Corporate RestructuringPoolbeg shareholders are expected to receive 0.03 shares of Hookipa for each Poolbeg share, resulting in approximately 55% of the equity of the combined entity.
Bears Say
Financial StabilityHookipa had approximately $60M in cash, which is believed to be insufficient to support the company to realize meaningful value inflection points from its own pipeline.
Shareholder DilutionHookipa plans to raise approximately $30M through a primary private placement, which is expected to lead to significant dilution for current Hookipa shareholders.
Ownership Overview
2.02% Insiders
6.04% Mutual Funds
33.91% Other Institutional Investors
54.74% Public Companies and Individual Investors
HOOK FAQ
What was Hookipa Pharma’s price range in the past 12 months?
Hookipa Pharma lowest stock price was $0.72 and its highest was $6.69 in the past 12 months.
What is Hookipa Pharma’s market cap?
Hookipa Pharma’s market cap is $14.52M.
When is Hookipa Pharma’s upcoming earnings report date?
Hookipa Pharma’s upcoming earnings report date is Aug 07, 2025 which is in 21 days.
How were Hookipa Pharma’s earnings last quarter?
Hookipa Pharma released its earnings results on May 08, 2025. The company reported -$1.23 earnings per share for the quarter, missing the consensus estimate of -$1.04 by -$0.19.
Is Hookipa Pharma overvalued?
According to Wall Street analysts Hookipa Pharma’s price is currently Undervalued.
Does Hookipa Pharma pay dividends?
Hookipa Pharma does not currently pay dividends.
What is Hookipa Pharma’s EPS estimate?
Hookipa Pharma’s EPS estimate is -0.61.
How many shares outstanding does Hookipa Pharma have?
Hookipa Pharma has 9,799,053 shares outstanding.
What happened to Hookipa Pharma’s price movement after its last earnings report?
Hookipa Pharma reported an EPS of -$1.23 in its last earnings report, missing expectations of -$1.04. Following the earnings report the stock price went down -8.696%.
Which hedge fund is a major shareholder of Hookipa Pharma?
Currently, no hedge funds are holding shares in HOOK
Company Description
Hookipa Pharma
HOOKIPA Pharma Inc., a clinical stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase II clinical trial in patients awaiting kidney transplantation from cytomegalovirus-positive donors. Its lead oncology product candidates are HB-201 and HB-202 that are in Phase I/II clinical trial for the treatment of human papillomavirus 16-positive cancers. The company's preclinical stage products include HB-300 program for prostate cancer; and HB-700 for targeting mutated KRAS in pancreatic, colorectal, and lung cancer. HOOKIPA Pharma Inc. has a collaboration with Gilead Sciences, Inc. to collaborate on preclinical research programs to evaluate potential vaccine products using or incorporating its replicating and non-replicating technology platforms for the treatment, cure, diagnosis, or prevention of Hepatitis B Virus. The company was incorporated in 2011 and is headquartered in New York, New York.
HOOK Stock 12 Month Forecast
Average Price Target
$2.00
▲(66.67%Upside)